ExcelVite Passes US FDA Inspection
13 Jun 2017 --- PIC/S GMP-certified palm phytonutrients producer ExcelVite has announced the successful completion of its quality audit/inspection by the US Food and Drug Administration (FDA). The inspection was conducted over three days at its production site in Malaysia.
The company announced that its production plant and Quality Management System (QMS) were inspected according to FDA’s Code of Federal Regulation – Title 21 Current Good Manufacturing Practices (21 CFR-cGMP). There was no non-compliance within ExcelVite’s systems, and hence, no Non-Conformance was issued at the end of the inspection.
“As part of the company’s commitment to ensure that our QMS is compliant with current good manufacturing practice (cGMP), we are proud to know that our existing system meets the quality criteria and requirements of the US FDA. It is of utmost importance to ensure that the entire system is adhered to and implemented at all times in order to ensure product quality and safety, which is our commitment to customers,” says Ms. YT Chan, Quality Assurance Manager of ExcelVite.
“Being a dedicated and largest manufacturer and exporter of palm phytonutrients especially EVNol natural full spectrum tocotrienol complex and EVTene natural mixed-carotene complex, ExcelVite is committed to the highest level of product quality, safety and manufacturing standards. In addition to enforcing cGMP PIC/S Guide (Pharmaceutical Inspection Co-Operation Scheme’s Guide to Good Manufacturing Practice for Medicinal Products), ExcelVite is proud to have achieved this important milestone in the FDA audit. It represents and underscores our compliance with the 21 CFR-cGMP Guidelines that allows for continuous export to the United States,” says WH Leong, CEO of ExcelVite.
This is the second time that the US FDA has inspected ExcelVite’s manufacturing facility located in Chemor, Perak, Malaysia. The first inspection had been conducted in 2012.
To contact our editorial team please email us at editorial@cnsmedia.com
Subscribe now to receive the latest news directly into your inbox.
